Fernando Franco

Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non–Small-Cell Lung Cancer (NADIM phase II trial)

Mariano Provencio, Roberto Serna‐Blasco, Ernest Nadal et al. · Journal of Clinical Oncology · 2022 · 322 citations · Full text

Cisplatin resistance involves a metabolic reprogramming through ROS and PGC-1α in NSCLC which can be overcome by OXPHOS inhibition

Alberto Cruz‐Bermúdez, Raquel Laza‐Briviesca, Ramiro J. Vicente-Blanco et al. · Free Radical Biology and Medicine · 2019 · 207 citations · Full text

Cancer-associated fibroblasts modify lung cancer metabolism involving ROS and TGF-β signaling

Alberto Cruz‐Bermúdez, Raquel Laza‐Briviesca, Ramiro J. Vicente-Blanco et al. · Free Radical Biology and Medicine · 2018 · 139 citations · Full text

Pathology, Cancer-associated Fibroblasts, Cancer Biology +19

Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping

J. Zugazagoitia, Inmaculada Ramos, José Trigo et al. · Annals of Oncology · 2018 · 83 citations · Full text

Neoadjuvant chemo/immunotherapy for the treatment of stages IIIA resectable non-small cell lung cancer (NSCLC): A phase II multicenter exploratory study—NADIM study-SLCG.

Mariano Provencio-Pulla, Ernest Nadal-Alforja, Manuel Cobo et al. · Journal of Clinical Oncology · 2018 · 68 citations

Surgical Oncology, Medicine, High Response Rate +12